Gain deeper insight into your drug candidates' potential with validated in vivo models.
Our platforms assess efficacy, mechanism of action, and host–disease interactions across therapeutic areas. Partner with our scientific team to choose the right in vivo model, design, and readout for your goals.
From cell-derived xenografts, syngeneic, and humanized models, to orthotopic systems with IVIS imaging and genetically engineered murine models, we tailor each study to maximize relevance, reproducibility, and decision-making confidence.
Cell Line-Derived Xenograft (CDX) Models
A robust platform of validated in vivo models to accelerate your oncology drug discovery
Cell line-derived xenograft models are a cornerstone of oncology preclinical development, providing actionable insights into a drug’s efficacy and mechanism of action. They allow clients to advance programs efficiently, making informed decisions while optimizing time and resources.
Comprehensive In Vivo Assay Systems
Our platform offers multiple in vivo assay systems tailored to evaluate novel anticancer compounds. Each system is designed to capture specific drug properties, from tumor growth inhibition to mechanistic effects, ensuring high-quality, translatable data.
Validated and Diverse Models
Our collection includes over 50 validated CDX models, covering subcutaneous, orthotopic, and systemic formats. Metastasis models, both spontaneous and experimental, encompass major cancer types, including:
- Brain Cancer
- Breast Cancer
- Colon Cancer
- Kidney Cancer
- Liver Cancer
- Pancreatic Cancer
- Ovarian Cancer
- Leukemia
This well-characterized portfolio ensures flexibility in study design and supports robust preclinical evaluation of your drug candidates.
Related Materials:
Syngeneic Models
Validated syngeneic models and expert support to advance your immunotherapy research
Quickly assess your immunotherapy candidates with models featuring fully functional immune systems, enabling robust evaluation of single agents and combination strategies.
Why Choose Our Syngeneic Platform:
- Fully immunocompetent models derived from inbred mouse strains
- Checkpoint inhibitor benchmarking to validate studies against industry standards
- Rapid model selection using a curated database of well-characterized tumor lines
- Expert support on study design and preclinical strategy
Accelerate your immunotherapy development with reliable, translational, and well-characterized syngeneic models.
Related Materials:
Humanized Models
Evaluate human-specific immunotherapies with HSC and PBMC humanized models
Advance your antibody and immunotherapy programs with highly translational humanized models, developed in collaboration with top-tier suppliers. These platforms allow robust assessment of single agents, combination strategies, and novel targets in a human immune context.
Why Choose Our Humanized Platform:
- HSC-PDX models:
stable reconstitution of human immune lineages, including T cells and myeloid compartments, for patient-relevant studies - PBMC-humanized models:
rapid, cost-effective evaluation of T cell-targeted therapies and NK- or ADCC-based agents - Expert support:
study design guidance and mouse clinical trial experience to mimic clinical immune heterogeneity
Related Materials:
Orthotopic & Bioluminescent Models
Track tumor growth and metastasis in real-time with advanced IVIS imaging
Leverage our orthotopic and metastatic models to study cancer progression in a clinically relevant, organ-specific tumor microenvironment (TME). Tumor cells are luciferase-labeled, enabling non-invasive, real-time monitoring of primary tumor growth and metastatic spread.
Why Choose Our Orthotopic Bioluminescent Platform:
- Clinically relevant TME:
organ-specific implantation mimics human tumor–stroma–immune interactions - Real-time efficacy monitoring via bioluminescent imaging
- Advanced metastasis models for bone, brain, and other metastatic sites
- Flexible applications: syngeneic and xenograft lines for single-agent
and combination therapy studies
Gain deeper mechanistic insights, evaluate therapeutic strategies, and generate patient-relevant preclinical data with our validated orthotopic bioluminescent models.
Related Materials:
Genetically Modified Models
Validated syngeneic models and expert support to advance your immunotherapy research
As a CRO, we provide specialized expertise in the use of genetically engineered murine models, including knock-in (KI) and knock-out (KO) strains, to support antibody-based and immuno-oncology development programs.
Our experienced technical teams and fully equipped facilities enable efficient study execution with complex models, including humanized KI systems and Fc gamma receptor (FcγR)–relevant mice. These models are critical for evaluating antibody mechanisms of action, immune effector engagement, and in vivo pharmacology.
By delivering robust, decision-ready data, we help our clients de-risk programs, optimize development timelines, and advance high-quality candidates with confidence, providing actionable insights at every stage of preclinical development
Related Materials:
Frequently Asked Questions
How do you support model selection for my specific drug candidate?
Our scientific team works closely with clients to define the most appropriate in vivo model based on mechanism of action, therapeutic modality (e.g., small molecule, antibody, cell therapy), target biology, and translational objectives. We provide strategic guidance on study design, endpoints, and imaging approaches.
What is the difference between HSC- and PBMC-humanized models?
HSC-humanized models provide stable reconstitution of multiple human immune lineages, supporting long-term and patient-relevant studies. PBMC-humanized models offer a faster and cost-effective option, particularly suited for evaluating T cell-targeted therapies and NK/ADCC-driven mechanisms.
Do you support combination therapy studies?
Yes. Our platforms are designed to evaluate single agents and combination strategies, including checkpoint inhibitors, chemotherapy backbones, targeted therapies, and novel immunotherapeutic approaches.
How do you ensure reproducibility and decision-ready data?
We rely on validated model portfolios, standardized SOP-driven execution, curated tumor line databases, advanced imaging systems, and experienced scientific oversight. Our goal is to generate robust, translational, and actionable preclinical data that de-risk development and support confident go/no-go decisions
What is the difference between transgenic (genetically engineered) and humanized mouse models?
Transgenic models are genetically modified (e.g., knock-in/knock-out) to study specific genes, pathways, or immune components within a controlled murine background. Humanized models are engrafted with human cells (e.g., HSCs or PBMCs) to reconstitute elements of the human immune system, enabling evaluation of human-specific therapeutics such as antibodies and immunotherapies. Model selection depends on the therapeutic modality, mechanism of action, and translational goals.
When should I choose a subcutaneous CDX model versus an orthotopic model?
Subcutaneous CDX models are ideal for early efficacy, tumor growth inhibition (TGI), dose optimization, and rapid proof-of-concept studies. They are reproducible and well-suited for compound screening. Orthotopic models involve implantation in the organ of origin, recreating a clinically relevant tumor microenvironment. They are preferred when studying tumor–stroma–immune interactions, invasion, or metastasis, particularly with IVIS imaging for real-time monitoring. The choice should align with the study hypothesis and required translational depth.
Partner with Accelera’s Scientific Team
Let’s discuss how our preclinical toxicology and safety expertise can accelerate your drug development program.